Related Experiment Video

Updated: May 12, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

10.3K

Impact of Micafungin on Candida auris β-glucan Masking and Neutrophil Interactions

Mark V Horton1,2, Emily F Eix1,2, Chad J Johnson1

  • 1Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.

The Journal of Infectious Diseases
|February 8, 2024
PubMed

Insights

Echinocandin treatment of Candida auris shows minimal impact on immune cell interactions. This suggests limited effectiveness in boosting immune responses against this drug-resistant fungal pathogen.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Immunology

Background:

  • Candida auris is an emerging global health threat due to high mortality and drug resistance.
  • Echinocandins can enhance immune responses against Candida albicans by unmasking beta-glucan.
  • Understanding echinocandin effects on C. auris is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the impact of echinocandin treatment on beta-glucan exposure in Candida auris.
  • To analyze the interaction between echinocandin-treated C. auris and human neutrophils.

Main Methods:

  • Treatment of C. auris isolates with subinhibitory concentrations of echinocandins.
  • Assessment of beta-glucan unmasking.
  • Evaluation of human neutrophil functional responses (e.g., phagocytosis).

Main Results:

  • Subinhibitory echinocandin concentrations caused minimal beta-glucan unmasking in C. auris.
  • Neutrophil interactions with treated C. auris showed only subtle functional changes.
  • Phagocytic responses were not significantly altered by the treatment.

Conclusions:

  • Echinocandin treatment is unlikely to significantly enhance immune responses against C. auris.
  • Beta-glucan masking pathways differ between C. auris and C. albicans.
  • Alternative therapeutic strategies may be needed to combat C. auris infections.
Keywords:
CandidaCandida aurisglucaninnate immunityneutrophilphagocytosis

More Related Videos

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

13.8K
Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells09:27

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells

Published on: April 2, 2021

3.9K

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...